IMA: Ikena Oncology, Inc. Price-to-Revenue Coefficient

Symbol and logo of brand Ikena Oncology, Inc. (IMA)

Optimized raw material delivery channels minimize supply chain disruption risks for ImageneBio Inc (IMA). Business revenues are based on bringing targeted oncology therapies to market. The synergy between biomarker discovery and drug development determines the dynamics of the enterprise value-to-revenue ratio, where the indicator value is 0.00. This chart allows for an assessment of the fairness of the stock's market price through the lens of real cash flows.

IMA ikenaoncology.com: P/S Multiple in the range 07/29/2025 - 07/29/2025

Analytical breakdowns for ImageneBio Inc (IMA)

- current quotes and average value forecast:
Market Price ikenaoncology.com|IMA - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Ikena Oncology, Inc.|IMA - Total Company Value
- company book value details:
Accounting Value per Share Ikena Oncology|IMA - Book Capitalization|Market Capitalization to Book Value Ratio ikenaoncology.com|IMA - Company Total Assets
- issuer credit burden and liquidity indicators:
Debt to Capital Ratio ImageneBio Inc|IMA - Long-Term Debt to Capital|Current Liabilities to Capital ikenaoncology.com|IMA - Company Debts|Debt to Book Value Ratio Ikena Oncology, Inc.|IMA - Company Long-Term Debts|Short-Term Debt Ikena Oncology|Quick Liquidity ikenaoncology.com
- business earnings and investment ratios data:
IMA - Net Profit|Company Profit Forecast ImageneBio Inc|IMA - Price to Earnings Ratio|Projected Price to Earnings Ratio ikenaoncology.com|IMA - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Ikena Oncology, Inc.|IMA - Operating profit EBITDA|Net earnings per share for the last four quarters Ikena Oncology|IMA - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months ikenaoncology.com|IMA - Earnings growth in current year|Expected earnings per share growth for next year ImageneBio Inc
- issuer revenue and sales details:
IMA - Revenue and Sales Volume|Company Future Sales ikenaoncology.com|IMA - Price-to-Revenue Ratio|Forward Price-to-Revenue Multiple Ikena Oncology, Inc.
Fundamental company analysis:ImageneBio (IMA)
Manufactured product of Ikena Oncology, Inc.

In the biopharmaceutical sector, ImageneBio Inc (IMA) focuses on the validation of oncology targets, delegating costly production stages to major partners. The P/S ratio reflects the relationship between market capitalization and sales volume, demonstrating the valuation's sensitivity to operational successes. This indicator measures the cost of each unit of revenue, making it possible to determine the extent of the premium paid for future growth. Analysis via the price-to-sales valuation reveals abnormal spikes in capitalization, signaling potential risks or entry points.

Competing companies

ARGX - Price to Sales|P/S Multiple BNTX (BioNTech)|Price-to-Revenue Coefficient Abivax Pharma (ABVX)|ADMA - Price-to-Revenue Ratio|Protagonist Corp (PTGX) - Market Cap to Revenue|IMVT: P/S Multiple|kiniksa.com (KNSA) - P/S Multiple|GRFS (Grifols) - P/S Multiple|ADPT - Price-to-Revenue Multiple|P/S Multiple CLDX|AUPH - Price to Sales|Price-to-Revenue Ratio BioCryst BCRX|VERA: Market Cap to Revenue Ratio|Dianthus Therapeutics, Inc. - P/S Multiple|Price to Sales Pharvaris NV|ABCL: P/S Multiple|TRML (Tourmaline) - Price-to-Revenue Ratio|PGEN (Precigen, Inc.) - P/S Multiple|pharming.com (PHAR) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Nektar Therapeutics Inc. (NKTR)|UPB - Price to Sales|Zenas Biopharma, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IMNM|Gossamer Bio, Inc. - P/S Multiple|Price-to-Revenue Coefficient kalvista.com KALV|Septerna (SEPN) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio PVLA|SVRA (Savara Corp) - P/S Multiple|Market Cap to Revenue Rigel Corp (RIGL)|P/S Multiple ANAB|Price-to-Revenue Coefficient astriatx.com|Price-to-Revenue Ratio enGene ENGN|RAPT - Market Cap to Revenue|Aerovate - P/S Multiple|ACRS - P/S Multiple|Kyverna Therapeutics (KYTX) - Price-to-Revenue Ratio|Price-to-Sales Ratio TLSA (tizianalifesciences.com)|CABA (Cabaletta Bio) - P/S Multiple|VTYX: Market Capitalization-to-Revenue Ratio|P/S Multiple THTX|P/S Multiple Avalo Therapeutics Inc (AVTX)|Price-to-Revenue Ratio Eledon Pharmaceuticals ELDN|Market Capitalization-to-Revenue Ratio AGEN|CLYM - Price-to-Revenue Ratio|Zura Bio Ltd (ZURA) - Market Cap to Revenue|ATYR: P/S Multiple|Adagene Inc. (ADAG) - P/S Multiple|Market Cap to Revenue STTK|EQ: Market Capitalization-to-Revenue Ratio|P/S Multiple CNTB|Price-to-Revenue Coefficient immunic-therapeutics.com|Price-to-Revenue Ratio Atara Bio ATRA|IFRX - Market Cap to Revenue|XFOR - Price-to-Revenue Ratio|Adicet Bio (ACET) - Market Cap to Revenue|CELU (celularity.com) - Market Cap to Revenue|INmune Bio Inc (INMB) - P/S Multiple|Price-to-Revenue Ratio Barinthus Bio|Market Cap to Revenue Ratio KZR (Kezar Life Sciences Inc)|P/S Multiple SABS|AKTX - Price to Sales|P/S Multiple ENLV (Enlivex Therapeutics Ltd.)|Price-to-Revenue Coefficient Q32 Bio Inc (QTTB)|GOVX - Price-to-Revenue Ratio|Edesa Biotech Corp (EDSA) - Market Cap to Revenue|IBIO: P/S Multiple|Carisma Therapeutics Inc. (CARM) - P/S Multiple|XTLB (XTL Biopharmaceuticals Ltd.) - P/S Multiple|BOLT - Price-to-Revenue Multiple|P/S Multiple HCWB|APVO - Price to Sales|Price-to-Revenue Ratio AIM ImmunoTech Inc. AIM|ADTX: Market Cap to Revenue Ratio|GRI Bio - P/S Multiple|Price to Sales XORTX Therapeutics Inc|HIND: P/S Multiple|REVB (Revelation Biosciences Corp) - Price-to-Revenue Ratio|INDP (Indaptus Therapeutics) - P/S Multiple|scinai.com (SCNI) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio CalciMedica, Inc. (CALI)|AFMD - Price to Sales|Allakos - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio HOOK|IGM Bio - P/S Multiple|Price-to-Revenue Coefficient iteostherapeutics.com ITOS|Ocean Biomedical (OCEA) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio TCBP|THRD (Third Harmonic Bio, Inc) - P/S Multiple